Panacea Biotec Ltd
Incorporated in 1984, Panacea Biotec Ltd is a research-based biotechnology company[1]
- Market Cap ₹ 2,483 Cr.
- Current Price ₹ 406
- High / Low ₹ 648 / 292
- Stock P/E
- Book Value ₹ 46.5
- Dividend Yield 0.00 %
- ROCE -3.39 %
- ROE -9.97 %
- Face Value ₹ 1.00
Pros
Cons
- Stock is trading at 8.72 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -4.39% over last 3 years.
- Earnings include an other income of Rs.19.1 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 679 | 647 | 530 | 184 | 96 | 158 | 344 | 236 | 257 | 360 | 310 | 413 | 436 | |
| 612 | 534 | 460 | 192 | 243 | 248 | 343 | 308 | 320 | 345 | 317 | 431 | 443 | |
| Operating Profit | 68 | 113 | 70 | -8 | -147 | -90 | 0 | -73 | -63 | 14 | -7 | -18 | -7 |
| OPM % | 10% | 17% | 13% | -4.4% | -152% | -57% | 0.1% | -31% | -24% | 3.9% | -2.2% | -4.3% | -1.7% |
| 28 | 75 | 16 | 84 | 322 | -14 | 21 | 13 | 34 | 25 | 17 | 18 | 19 | |
| Interest | 93 | 115 | 104 | 103 | 105 | 5 | 8 | 7 | 10 | 14 | 15 | 25 | 26 |
| Depreciation | 66 | 71 | 66 | 34 | 33 | 27 | 27 | 26 | 24 | 21 | 20 | 19 | 18 |
| Profit before tax | -63 | 1 | -84 | -61 | 37 | -136 | -13 | -94 | -63 | 4 | -26 | -44 | -33 |
| Tax % | 3% | 38% | -14% | 17% | 29% | 13% | 12% | 0% | 40% | 16% | -42% | -32% | |
| -65 | 1 | -73 | -72 | 27 | -153 | -14 | -94 | -88 | 4 | -15 | -30 | -22 | |
| EPS in Rs | -10.64 | 0.14 | -11.85 | -11.73 | 4.33 | -24.97 | -2.36 | -15.27 | -14.28 | 0.58 | -2.48 | -4.87 | -3.55 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 4% |
| 3 Years: | 17% |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | -21% |
| 3 Years: | 19% |
| TTM: | -167% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 6% |
| 3 Years: | 43% |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | -17% |
| 5 Years: | -13% |
| 3 Years: | -4% |
| Last Year: | -10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 |
| Reserves | 517 | 518 | 450 | 382 | 412 | 887 | 502 | 409 | 320 | 323 | 308 | 279 |
| 1,031 | 1,035 | 1,023 | 970 | 689 | 67 | 65 | 84 | 102 | 125 | 228 | 265 | |
| 325 | 248 | 303 | 316 | 335 | 179 | 217 | 263 | 296 | 300 | 327 | 302 | |
| Total Liabilities | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 | 869 | 852 |
| 1,060 | 988 | 942 | 891 | 496 | 499 | 464 | 454 | 435 | 423 | 416 | 457 | |
| CWIP | 17 | 19 | 28 | 37 | 3 | 4 | 13 | 1 | 28 | 97 | 119 | 91 |
| Investments | 395 | 395 | 345 | 345 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| 408 | 406 | 467 | 401 | 940 | 633 | 313 | 307 | 260 | 234 | 334 | 303 | |
| Total Assets | 1,879 | 1,807 | 1,782 | 1,673 | 1,442 | 1,138 | 790 | 762 | 724 | 754 | 869 | 852 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 45 | 98 | 104 | 172 | 107 | -83 | 38 | -53 | -11 | 33 | 4 | 0 | |
| -29 | 23 | -18 | -3 | -10 | -17 | -37 | 40 | 2 | -47 | -61 | 0 | |
| -11 | -129 | -91 | -164 | -98 | 109 | -7 | 10 | 9 | 13 | 90 | 0 | |
| Net Cash Flow | 5 | -8 | -5 | 6 | -2 | 10 | -6 | -3 | 1 | -1 | 33 | 0 |
| Free Cash Flow | 41 | 97 | 80 | 157 | 102 | -69 | 28 | -59 | -10 | -36 | -49 | 0 |
| CFO/OP | 71% | 69% | 140% | -2,130% | -73% | 83% | 8,010% | 71% | 15% | 247% | -73% | 0% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 54 | 80 | 121 | 283 | 96 | 41 | 37 | 36 | 17 | 11 | 25 | 27 |
| Inventory Days | 178 | 233 | 304 | 618 | 203 | 619 | 180 | 421 | 260 | 278 | 541 | 218 |
| Days Payable | 236 | 295 | 490 | 1,002 | 373 | 847 | 257 | 472 | 289 | 299 | 586 | 231 |
| Cash Conversion Cycle | -4 | 17 | -65 | -102 | -74 | -188 | -39 | -15 | -12 | -10 | -21 | 15 |
| Working Capital Days | -229 | -80 | -133 | -682 | -49 | 892 | 4 | -63 | -135 | -79 | -141 | -8 |
| ROCE % | 2% | 4% | 4% | 3% | -14% | -8% | -1% | -16% | -13% | 4% | -2% | -3% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Countries Exported to (Pharmaceutical Formulations) count |
|
|||||||||
| Countries where Vaccines are Registered count |
||||||||||
| Electricity Consumption per Unit (Vaccines) kWh per 1000 doses |
||||||||||
| Patents Granted Globally count |
||||||||||
| Pediatricians Covered count |
||||||||||
| Total Distributors (Pharma + Vaccines) count |
||||||||||
| Vaccine Production Volume thousand doses |
||||||||||
| Vaccine Segment Revenue Share % |
||||||||||
| R&D Expenditure (Percentage of Turnover) % |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper copies of the public notice, requesting shareholders to register their email addresses with the Company in connection with ensuing AGM of the Company.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Please find attached of the extract of statement of Unaudited Financial Results for the quarter ended 30.06.2026, published on 14.08.2026.
- Standalone And Consolidated Unaudited Financial Results (Provisional) Along With Limited Review Report For The Quarter Ended June 30, 2026
-
Board Meeting Outcome for Outcome Of Board Meeting Held On August 13, 2026
- Q1 FY27 results: standalone profit ₹139 lakh, consolidated profit ₹220 lakh; AGM on Sep 29, 2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Please find attached newspaper copies regarding notice intimating the investors about the opening of Special Window for transfer and dematerialisation of physical shares.
Annual reports
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
-
Annual Report 2019
from bse
-
Annual Report 2018
from bse
-
Annual Report 2017
from bse
-
Annual Report 2016
from bse
-
Annual Report 2015
from bse
-
Annual Report 2014
from bse
-
Annual Report 2013
from nse
-
Annual Report 2013
from bse
-
Annual Report 2012
from nse
Business Overview:[1]
a) PBL is in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food & nutrition products
b) It is one of the largest Vaccine Manufacturing Company in India and is acknowledged by the United Nations (UN) Health Agencies in partnering the Global Polio Eradication Initiative (GPEI) with supplies of billions of doses of WHO Pre-qualified Polio vaccines in 50+ countries worldwide as a sequel to the completion of full range of Oral polio vaccines (tOPV, mOPV1, mOPV3 & bOPV (Type1&Type3)
c) It is the first company to have developed fully liquid Pentavalent vaccine (DTwP-Hep B+Hib) EasyFive and world’s first fully-liquid wP-IPV based Hexavalent vaccine (DTwP +HepB +Hib +IPV) EasySix